DiagnaMed Accelerates Commercialization of CERVAI™ Brain Health AI Platform with Acceptance into the SOPHIE Program
TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare company, is pleased to announce it has been accepted into the Southern Ontario Pharmaceutical & Health Innovation Ecosystem (“SOPHIE”) Program to accelerate the clinical and commercialization efforts in Canada for the Company’s CERVAI™ Brain Health AI Platform. The SOPHIE program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. DiagnaMed can leverage funding to work directly with an academic or hospital partner in Hamilton’s ecosystem, such as McMaster University, Mohawk College, Hamilton Health Sciences, and St Joseph’s Health Centre Foundation.
A world first, CERVAI™ consists of a Brain Age™ Estimation and Brain Health Assessment tool. The Brain Age™ Estimation tool includes a novel electroencephalogram headset and machine-learning model. It integrates proprietary software into unified and standardized data recording protocols. The Brain Health Assessment tool generates clinician-observed measures and a brain health score. These combined allow users to be proactive in achieving their brain health goals. Future versions of CERVAI™ will incorporate OpenAI’s GPT platform to develop personalized treatment plans.
DiagnaMed expects the launch of the initial commercial version of CERVAI™ in December 2023 and first sales to occur throughout Q1-2024. CERVAI™ can be available at health centers, doctor offices, hospitals, clinics, pharmacies, and homes. Discussions with clinics and research centers for CERVAI™ in Canada and the U.S. are taking place. DiagnaMed plans to partner with digital health companies for international commercialization.
Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We are happy to be accepted into the SOPHIE program to accelerate the clinical and commercialization initiatives of CERVAI™, our novel brain health AI platform. As we near the commercial launch for CERVAI™, we continue leveraging expertise from Canada’s respected life sciences ecosystem to improve CERVAI™’s positioning and global expansion goals.”
The SOPHIE Program is a three-year program funded by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), delivered in partnership with Innovation Factory’s commercialization services and the Synapse Life Science Consortium’s strategic network to leverage access to Hamilton’s unique life sciences capabilities and research expertise.
The CERVAI™ Healthcare Provider Network partnership program is open for enrollment. If interested in joining or learning more, prospective partners are encouraged to visit https://www.diagnamed.com/hcpartner.
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare company, is focused on developing and commercializing CERVAI™, a proprietary brain health AI platform. Learn more at DiagnaMed.com.
For more information about DiagnaMed, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three and nine months ended June 30, 2023 (“MD&A”), dated August 24, 2023,which is available on the Company’s profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
